Survival Status and Risk Factors for Mortality Among Multidrug-resistant Tuberculosis Patients in Addis Ababa, Ethiopia: A Retrospective Follow-up Study

Overview

Journal J Clin Tuberc Other Mycobact Dis

Date 2023 Sep 28

PMID 37767135

Authors

Genanew Kassie Getahun

Elias Gezahegn

Getabalew Endazenawe

Tewodros Shitemaw

Zelalem Negash

Samuel Dessu

Affiliations

Soon will be listed here.

Abstract

Background: Tuberculosis continues to be a major health concern around the world. It kills an estimated 1.6 million people each year. The World Health Organization (WHO) removed Ethiopia from its list of thirty countries having a high prevalence of MDR/RR-TB in 2021. As a result, the aim of this study was to assess the current context of survival status and risk factors of multidrug-resistant tuberculosis patients in Addis Ababa, Ethiopia, in 2022.

Methods: An institutional-based retrospective cohort study with 245 patients was undertaken using multidrug-resistant tuberculosis patients who were recruited from January 1st, 2018 to December 30th, 2021, in St. Peter's specialized hospital. To find independent predictors of survival status, Cox regression analysis was used. An adjusted hazard ratio with a 95% confidence interval and a p-value of < 0.05 was used to establish association and statistical significance.

Results: The result of the study revealed that the incidence of mortality in this study was 13.1% (95% CI: 10.3-16.5). Moreover, being male (AOR = 3.7: 95% CI = 1.2, 11.4), old age (AOR = 14: 95% CI = 3.0, 60.4), site of TB (AOR = 0.2: 95% CI = 0.03, 0.6), and presence of comorbidity (AOR = 9.2: 95% CI = 2.4, 35.3), were independent predictors of time to death.

Conclusion: Generally, the death rate among research participants was high. Moreover, male gender, old age, site of tuberculosis, and presence of other comorbidity were predictors of mortality among MDR-TB patients.

References

Bassili A, Fitzpatrick C, Qadeer E, Fatima R, Floyd K, Jaramillo E . A systematic review of the effectiveness of hospital- and ambulatory-based management of multidrug-resistant tuberculosis. Am J Trop Med Hyg. 2013; 89(2):271-80. PMC: 3741248. DOI: 10.4269/ajtmh.13-0004. View

Sreeramareddy C, Panduru K, Verma S, Joshi H, Bates M . Comparison of pulmonary and extrapulmonary tuberculosis in Nepal- a hospital-based retrospective study. BMC Infect Dis. 2008; 8:8. PMC: 2245948. DOI: 10.1186/1471-2334-8-8. View

Ketema D, Muchie K, Andargie A . Time to poor treatment outcome and its predictors among drug-resistant tuberculosis patients on second-line anti-tuberculosis treatment in Amhara region, Ethiopia: retrospective cohort study. BMC Public Health. 2019; 19(1):1481. PMC: 6839158. DOI: 10.1186/s12889-019-7838-2. View

Gallo J, Pinhata J, Simonsen V, Galesi V, Ferrazoli L, Oliveira R . Prevalence, associated factors, outcomes and transmission of extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in São Paulo, Brazil: a cross-sectional study. Clin Microbiol Infect. 2017; 24(8):889-895. DOI: 10.1016/j.cmi.2017.11.015. View

Floyd K, Glaziou P, Zumla A, Raviglione M . The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. Lancet Respir Med. 2018; 6(4):299-314. DOI: 10.1016/S2213-2600(18)30057-2. View

Paul R . The Threat of Multidrug-resistant Tuberculosis. J Glob Infect Dis. 2018; 10(3):119-120. PMC: 6100333. DOI: 10.4103/jgid.jgid_125_17. View

Brust J, Gandhi N, Carrara H, Osburn G, Padayatchi N . High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung Dis. 2010; 14(4):413-9. PMC: 3005763. View

Alene K, Viney K, McBryde E, Tsegaye A, Clements A . Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia. Trop Med Int Health. 2016; 22(3):351-362. DOI: 10.1111/tmi.12826. View

Perez-Butragueno M, Ramos-Rincon J, Tesfamariam A, Comeche B, Mohammed N, Tiziano G . Impact of Xpert MTB/RIF in the Diagnosis of Childhood Tuberculosis in Rural Ethiopia. J Trop Pediatr. 2022; 68(4). DOI: 10.1093/tropej/fmac055. View

10.

Belachew T, Yaheya S, Tilahun N, Gebrie E, Seid R, Nega T . Multidrug-Resistant Tuberculosis Treatment Outcome and Associated Factors at the University of Gondar Comprehensive Specialized Hospital: A Ten-Year Retrospective Study. Infect Drug Resist. 2022; 15:2891-2899. PMC: 9172731. DOI: 10.2147/IDR.S365394. View

11.

Izudi J, Tamwesigire I, Bajunirwe F . Treatment success and mortality among adults with tuberculosis in rural eastern Uganda: a retrospective cohort study. BMC Public Health. 2020; 20(1):501. PMC: 7161267. DOI: 10.1186/s12889-020-08646-0. View

12.

Girum T, Muktar E, Lentiro K, Wondiye H, Shewangizaw M . Epidemiology of multidrug-resistant tuberculosis (MDR-TB) in Ethiopia: a systematic review and meta-analysis of the prevalence, determinants and treatment outcome. Trop Dis Travel Med Vaccines. 2018; 4:5. PMC: 6000958. DOI: 10.1186/s40794-018-0065-5. View

13.

Hochberg N, Horsburgh Jr C . Prevention of tuberculosis in older adults in the United States: obstacles and opportunities. Clin Infect Dis. 2013; 56(9):1240-7. PMC: 3693488. DOI: 10.1093/cid/cit027. View

14.

Nahid P, Mase S, Migliori G, Sotgiu G, Bothamley G, Brozek J . Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019; 200(10):e93-e142. PMC: 6857485. DOI: 10.1164/rccm.201909-1874ST. View

15.

Tola H, Holakouie-Naieni K, Mansournia M, Yaseri M, Gamtesa D, Tesfaye E . National treatment outcome and predictors of death and treatment failure in multidrug-resistant tuberculosis in Ethiopia: a 10-year retrospective cohort study. BMJ Open. 2021; 11(8):e040862. PMC: 8356165. DOI: 10.1136/bmjopen-2020-040862. View

16.

Akkerman O, Ter Beek L, Centis R, Maeurer M, Visca D, Munoz-Torrico M . Rehabilitation, optimized nutritional care, and boosting host internal milieu to improve long-term treatment outcomes in tuberculosis patients. Int J Infect Dis. 2020; 92S:S10-S14. DOI: 10.1016/j.ijid.2020.01.029. View

17.

Javaid A, Shaheen Z, Shafqat M, Khan A, Ahmad N . Risk factors for high death and loss-to-follow-up rates among patients with multidrug-resistant tuberculosis at a programmatic management unit. Am J Infect Control. 2016; 45(2):190-193. DOI: 10.1016/j.ajic.2016.07.026. View

18.

Menzies N, Quaife M, Allwood B, Byrne A, Coussens A, Harries A . Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. Lancet Glob Health. 2021; 9(12):e1679-e1687. PMC: 8609280. DOI: 10.1016/S2214-109X(21)00367-3. View

19.

Verdecchia M, Keus K, Blankley S, Vambe D, Ssonko C, Piening T . Model of care and risk factors for poor outcomes in patients on multi-drug resistant tuberculosis treatment at two facilities in eSwatini (formerly Swaziland), 2011-2013. PLoS One. 2018; 13(10):e0205601. PMC: 6192624. DOI: 10.1371/journal.pone.0205601. View

20.

Hamusse S, Demissie M, Teshome D, Lindtjorn B . Fifteen-year trend in treatment outcomes among patients with pulmonary smear-positive tuberculosis and its determinants in Arsi Zone, Central Ethiopia. Glob Health Action. 2014; 7:25382. PMC: 4170110. DOI: 10.3402/gha.v7.25382. View